The dosimetry estimate using increasing dose of 225Ac-PSMA-617 targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage PC patients. The gene discussed is FOLH1; the disease is pachyonychia congenita.